Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease

Objective: Intravenous immunoglobulin (IVIG) therapy is a useful first-line treatment for Kawasaki disease (KD); however, 10–20% of patients fail to respond and require additional IVIG. Soluble CD163 (sCD163) is considered a biomarker for macrophage activation. There are no reports measuring serum s...

Full description

Bibliographic Details

Published in:	Frontiers in Pediatrics
Main Authors:	Yoshihiro Azuma, Yasuo Suzuki, Seigo Okada, Chie Matsuguma, Hiroyuki Wakiguchi, Yuji Ohnishi, Takashi Furuta, Akiko Miyake, Hiroki Yasudo, Kiyoshi Ichihara, Shouichi Ohga, Shunji Hasegawa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-04-01
Subjects:	intravenous immunoglobulin Kawasaki disease macrophage soluble CD163 sCD163
Online Access:	https://www.frontiersin.org/article/10.3389/fped.2020.00148/full